Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma

Bone Marrow Transplantation volume 55, pages 2322–2325 (2020)Cite this article

Subjects

High dose chemotherapy followed by autologous hematopoetic stem cell transplantation (HCT) is the standard of care in chemosensitive transplant eligible patients with relapsed or refractory classical Hodgkin lymphoma (r/r cHL) [1, 2]. Relapse remains the most common cause of treatment failure after HCT and a number of studies reported on prognostic factors that help stratify patients. The Centre of International Blood and Marrow Transplant Research (CIBMTR) reported a validated prognostic model for r/r cHL after HCT and identified the following risk factors in a weighted model; low performance status, refractory status post first line therapy, extra-nodal disease, and three or more chemotherapy regimens prior to HCT [3]. Patients were subsequently stratified into low, intermediate, or high risk disease with significant differences in outcome. Furthermore, complete metabolic response (CMR) pre-HCT assessed by positron emission tomography/computed tomography (PET/CT) was a powerful predictor of a favorable outcome in a number of studies [4,5,6].

Brentuximab vedotin (Bv) consolidation early post-HCT in high risk patients was associated with significantly improved progression free survival (PFS) with ~60% of patients achieving long term remissions [7]. Furthermore, the use of Bv within a salvage chemotherapy i.e., Bv containing salvage resulted in a higher rate of CMR than historical series of salvage with chemotherapy alone [8,9,10]. In light of the above, the aim of this analysis is to examine the outcome of r/r cHL patients receiving Bv containing salvage followed by consolidation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Progression free survival (PFS) and overall survival (OS) post autologous HCT.

References

  1. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–71.

    Article  CAS  Google Scholar 

  2. Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2015;21:1863–9.

    Article  Google Scholar 

  3. Hahn T, McCarthy PL, Carreras J, Zhang MJ, Lazarus HM, Laport GG, et al. Simplified validated prognostic model for progression-free survival after autologous transplantation for Hodgkin lymphoma. Biol Blood Marrow Transpl. 2013;19:1740–4.

    Article  Google Scholar 

  4. Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy. Haematologica. 2012;97:1073–9.

    Article  Google Scholar 

  5. Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119:1665–70.

    Article  CAS  Google Scholar 

  6. Damlaj M, Ghazi S, Syed G, Pasha T, Gmati G, Salama H, et al. Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transpl. 2017;52:1342–4.

    Article  CAS  Google Scholar 

  7. Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639–42.

    Article  CAS  Google Scholar 

  8. LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132:40–8.

    Article  CAS  Google Scholar 

  9. Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019;30:612–20.

    Article  CAS  Google Scholar 

  10. Abuelgasim KA, Alzahrani M, Alsharhan Y, Khairi M, Hommady M, Gmati G, et al. Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma. Bone Marrow Transpl. 2019;54:1168–72.

    Article  Google Scholar 

  11. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.

    Article  Google Scholar 

  12. Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, et al. Maintenance therapies for hodgkin and non-hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol. 2019;5:715–22.

    Article  Google Scholar 

  13. Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M, et al. Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the HOVON/LLPC Transplant BRaVE study. Haematologica. 2019;104:e151–3.

    Article  CAS  Google Scholar 

  14. Kort J, Chidiac A, El Sayed R, Massoud R, Nehme R, Bazarbachi A, et al. Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma. 2020:1–4.

Download references

Author information

Authors and Affiliations

  1. Division of Hematology & HSCT, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia

    Moussab Damlaj, Khadega A. Abuelgasim, Ayman Alhejazi, Bader Alahmari, Ahmed Alaskar & Mohsen Alzahrani

  2. King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

    Moussab Damlaj, Khadega A. Abuelgasim, Ayman Alhejazi, Bader Alahmari, Ahmed Alaskar & Mohsen Alzahrani

  3. King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

    Moussab Damlaj, Khadega A. Abuelgasim, Ayman Alhejazi, Bader Alahmari, Ahmed Alaskar & Mohsen Alzahrani

Authors
  1. Moussab Damlaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Khadega A. Abuelgasim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ayman Alhejazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bader Alahmari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ahmed Alaskar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohsen Alzahrani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Moussab Damlaj.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Damlaj, M., Abuelgasim, K.A., Alhejazi, A. et al. Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transplant 55, 2322–2325 (2020). https://doi.org/10.1038/s41409-020-0935-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-020-0935-0

This article is cited by

Search

Advanced search

Quick links